Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct:29:102235.
doi: 10.1016/j.nano.2020.102235. Epub 2020 Jun 10.

Ion channel formation by N-terminally truncated Aβ (4-42): relevance for the pathogenesis of Alzheimer's disease

Affiliations

Ion channel formation by N-terminally truncated Aβ (4-42): relevance for the pathogenesis of Alzheimer's disease

Abhijith G Karkisaval et al. Nanomedicine. 2020 Oct.

Abstract

Aβ deposition is a pathological hallmark of Alzheimer's disease (AD). Besides the full-length amyloid forming peptides (Aβ1-40 and Aβ1-42), biochemical analyses of brain deposits have identified a variety of N- and C-terminally truncated Aβ variants in sporadic and familial AD patients. However, their relevance for AD pathogenesis remains largely understudied. We demonstrate that Aβ4-42 exhibits a high tendency to form β-sheet structures leading to fast self-aggregation and formation of oligomeric assemblies. Atomic force microscopy and electrophysiological studies reveal that Aβ4-42 forms highly stable ion channels in lipid membranes. These channels that are blocked by monoclonal antibodies specifically recognizing the N-terminus of Aβ4-42. An Aβ variant with a double truncation at phenylalanine-4 and leucine 34, (Aβ4-34), exhibits unstable channel formation capability. Taken together the results presented herein highlight the potential benefit of C-terminal proteolytic cleavage and further support an important pathogenic role for N-truncated Aβ species in AD pathophysiology.

Keywords: Amyloid; Electrophysiology; Oligomers; Truncated Aβ peptides.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1:
Figure 1:. Biophysical and structural analysis of Aβ4–42 and Aβ4–34 truncated peptides.
The purity of the peptides was assessed via MALDI-TOF (A) performed in a Bruker Daltonics Autoflex MALDI-TOF mass spectrometer (Bremen, Germany) in linear mode using standard instrument settings at the New York University Mass Spectrometry Core for Neuroscience. External calibration was performed using human adrenocorticotropic hormone peptide 18–39 (average mass = 2465.68 Da) and insulin (average mass = 5733.49 Da). In all cases MS spectra were processed and analyzed by FlexAnalysis (Bruker Daltonics). The different Aβ homologues, pre-treated in HFIP and reconstituted in physiologic salt concentration containing buffer, were incubated at 37°C for up to 2 hours. (B) CD spectra of Aβ4–42 (red line) and Aβ4–34 (black line) incubated 2h under physiological salt concentrations. Graph is representative of three independent experiments; (C) Fluorescence evaluation of Thioflavin T binding to the respective synthetic homologues (50 μM) either freshly reconstituted (open bars) or after 2h incubation (patterned bars). Results are expressed in arbitrary units (A.U.) and represent the mean ± SEM of three independent experiments after subtraction of blank levels. (D) Structural assessment of Aβ4–42 2h oligomerization visualized by EM after negative staining. (E) EM analysis of Aβ4–34 oligomerization after 2h incubation. In both (D) and (E), bar represents 100 nm
Figure 2:
Figure 2:. AFM images (height and amplitude error) of Aβ4–42 and Aβ4–34 interaction with DOPC bilayer.
A) Aβ4–42 and B) Aβ4–34 incubated on plane mica surface show distribution of monomers and oligomers. The white horizontal line depicts a section through the scanned area whose corresponding profile is shown below the image (A: scan size = 1.4um, height scale = 1.9nm; B: scan size = 1.4um, height scale = 3.2nm).
Figure 3:
Figure 3:. AFM images of amyloid beta ion channels when reconstituted in lipid bilayer.
A) Aβ4–42 reconstituted DOPC bilayer showing clusters of protein distributed (scan size = 3.5um, height scale = 9.5nm). B) Aβ4–34 reconstituted DOPC bilayer showing clusters of protein distributed (scan size = 1.2um, height scale = 5.6nm). C.) Aβ4–42 reconstituted DOPC bilayer at low peptide concentration (1:1000) shows intact bilayer with oligomeric peptides (blue dotted circles) in pore-like morphology. The inset in C) shows the pore-like structure in isometric view (scan sizes – 1μm, inset scan size 50nm, height scale 2.3nm). D) Amplitude error (which is proportional to the feedback signal and very sensitive to height changes on the surface) image of Aβ4–34 reconstituted DOPC bilayer at low peptide concentration (1:1000) shows intact bilayer with oligomeric peptides (black dotted circles) in pore-like morphology. The inset in D) shows the pore-like structure in isometric view. (scan sizes = 650nm, inset scan size = 60nm; height scale = 4.6mV)
Figure 4.
Figure 4.. Lipid bilayer membrane conductivity initiated by truncated Aβ peptides.
A) Conductivity initiated by Aβ4–42 peptide. B) Conductivity initiated by Aβ4–34 peptide. C) Aβ4–42 conductivity inhibition by monoclonal antibody 18H6. In all cases: chamber solution contains 100 mM NaCl, 20 mM Tris-Citrate buffer pH 7.4. Membrane formed from POPE/POPG 2:1 w/w, final concentration of lipids 1.5% in n-heptane. Top lines represent transmembrane currents, bottom lines - holding potential.

Similar articles

Cited by

References

    1. Cabrera E, Mathews P, Mezhericher E, et al. Aβ truncated species: implications for brain clearance mechanisms and amyloid plaque deposition. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 1864(1), 208–225 (2018). - PMC - PubMed
    1. Laurijssens B, Aujard F, Rahman A. Animal models of Alzheimer’s disease and drug development. Drug Discovery Today: Technologies. 10(3), e319–e327 (2013). - PubMed
    1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences. 82(12), 4245–4249 (1985). - PMC - PubMed
    1. Rostagno A, Holton J, Lashley T, Revesz T, Ghiso J. Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cellular and molecular life sciences. 67(4), 581–600 (2010). - PMC - PubMed
    1. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. Journal of proteome research. 5(4), 1010–1016 (2006). - PubMed

Publication types

MeSH terms